グラクソ・スミスクライン

 GSKのチャート


 GSKの企業情報

symbol GSK
会社名 GlaxoSmithKline Plc (グラクソ・スミスクライン)
分野(sector)   
産業(industry)   
業種 医薬品   医療関連(Health Care)
概要 グラクソ・スミスクライン(GlaxoSmithKline plc)は医療グループであり、ワクチン、市販薬(OTC)及び健康製品等の医薬品の作成、発見、開発、製造及び販売に従事する。同社は主に呼吸器、抗ウイルス、中枢神経系、心血管と泌尿生殖器、代謝、抗菌、腫瘍と嘔吐、皮膚、希少疾患、免疫・炎症、ワクチン及びヒト免疫不全ウイルス(HIV)等の治療分野向けに医薬品を提供している。同社は主に医薬品事業、ワクチン事業、およびコンシューマーヘルスケア事業の3事業区分により構成される。平成24年1月31日、同社は米国とカナダにおけるブランドをPrestige Brands Holdingsに売却完了した。同年8月、同社はHuman Genome Sciencesを買収した。平成25年1月30日、GSKは同社における持ち分の29.3%を追加買収した。  グラクソ・スミスクラインはイギリスの製薬メ―カ―。呼吸器、抗ウイルス、中枢神経、心臓血管、泌尿生殖器、がん、ワクチン、HIV分野で医療用医薬品を展開。主要製品は、鼻炎治療薬、肺疾患治療薬、抗血栓症薬、がん治療薬、抗HIV薬、ジフテリア・インフルエンザワクチンなど。オ―ラルケア製品、禁煙補助薬、市販薬、栄養補助製品などヘルスケア製品も提供。  
本社所在地 980 Great West Road Brentford Middlesex TW8 9GS GBR
代表者氏名 Emma Walmsley
代表者役職名 Chief Executive Officer Executive Director
電話番号 +44 20-8047-5000
設立年月日 36495
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 95490人
url www.gsk.com
nasdaq_url
adr_tso
EBITDA (百万ドル) 12929.04000
終値(lastsale)
時価総額(marketcap)
時価総額 (百万ドル) 103966.30000
売上高 (百万ドル) 40178.07000
企業価値(EV) (百万ドル) 132783.55500
当期純利益 (百万ドル) 4885.87000
決算概要 BRIEF: For the fiscal year ended 31 December 2018 GlaxoSmithKline plc (ADR) revenues increased 2% to £30.82B. Net income before extraordinary items increased 44% to £3.75B. Revenues reflect Vaccines segment increase of 14% to £5.89B US segment increase of 6% to £11.98B. Net income benefited from Consumer Healthcare segment income increase from £1.37B to £5.74B Unallocated segment loss decrease of 23% to £3.72B. Dividend per share remained flat at £0.80.

 GSKのテクニカル分析


 GSKのニュース

   Coronavirus: Luc Debruyne (ex-GSK) proposé comme conseiller spécial de la commissaire à la Santé  2021/02/19 12:46:13 Sudinfo
Le Belge Luc Debruyne, issu de la KULeuven et qui a eu une longue carrière au sein du géant pharmaceutique GlaxoSmithKline (GSK), devrait devenir la semaine prochaine le «conseiller spécial» des commissaires européens Stella Kyriakides (Santé) et Thierry Breton (Marché intérieur). L’objectif est d’enrichir la stratégie européenne de lutte contre le coronavirus et ses nouveaux variants de son expérience de l’industrie pharmaceutique.
   Global TIM-3 Inhibitor Pipeline Insight Report 2021: Emerging Drugs Include Cobolimab (GlaxoSmithKline) & BMS-986258 (Bristol-Myers Squibb) - ResearchAndMarkets.com  2021/02/19 10:42:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "TIM-3 Inhibitor - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering. This "TIM-3 inhibitor - Pipeline Insight, 2021," report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in TIM-3 inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and mole
   2 UK dividend stocks I’d add to my portfolio today  2021/02/18 16:21:47 The Motley Fool UK
National Grid (LSE:NG) and GlaxoSmithKline (LSE:GSK) are two of my top dividend stock picks from the FTSE 100. The post 2 UK dividend stocks I’d add to my portfolio today appeared first on The Motley Fool UK .
   How big is the Nanopharmaceuticals market? Abbott, GlaxoSmithKline plc., Eli Lilly and Company, Astrazeneca plc., Novavax, Inc., Stryker Corporation, OSI Pharmaceuticals  2021/02/18 14:01:19 OpenPR
The New Report “Nanopharmaceuticals Market” published by Coherent Market Insights, covers the market landscape and its growth prospects over the coming years. Coherent Market Insights Adds “Global Nanopharmaceuticals Market – Industry Trends and Forecast to 2028” new report to its research database. The
   GSK expands coronavirus antibody tie-up to include potential flu therapies -  2021/02/18 10:51:34 pharmaphorum
GlaxoSmithKline is expanding a coronavirus antibody collaboration with US biotech Vir, to include potential therapies for flu.
   Novartis negocia produzir vacina de outros laboratórios  2021/01/28 17:03:26 Valor Econômico
A farmacêutica suíça está em conversas com diversas empresas, disse o CEO Vas Narasimhan, à Bloomberg TV, sinalizando a possibilidade de acordo nos próximos dias ou semanas A Novartis está em negociações para produzir vacinas ou tratamentos contra o novo coronavírus desenvolvidos por outras empresas, em uma iniciativa do setor para aumentar a oferta em meio a disputas pelo acesso a esses produtos. A farmacêutica suíça está em conversas com diversas companhias, disse o CEO da empresa, Vas Narasimhan, à Bloomberg TV, sinalizando a possibilidade de acordo nos próximos dias ou semanas. “Estamos abertos a disponibilizar a capacidade de produção que temos em nossa rede”, acrescentou o executivo, se referindo a itens como anticorpos monoclonais e vacinas. Vas Narasimhan, CEO da Novartis Linkedin/Vas Narasimhan As negociações acontecem num momento de tensão global em que muitos países tentam adquirir vacinas para sair da pandemia. Após pesquisas próprias que não avançaram, a Sanofi vai turbinar a produção da vacina da Pfizer e BioNTech, anunciando na quarta-feira (27) que disponibilizará uma fábrica em Frankfurt.
   Global Smart Inhalers Market Future Prospects With Covid-19 Impact Analysis 2026 | Top Players-Teva Pharmaceutical Industries Ltd.; Adherium; Propeller Health; 3M; GlaxoSmithKline plc  2021/01/28 15:14:24 OpenPR
“Global Smart Inhalers Market–Industry Trends and Forecast to 2026” New Research Report Added to Databridgemarketresearch.com database. The report width Of pages : 350 Figures: 60 And Tables: 220 in it.Smart Inhalers market research report assists organization gain vital information
   Where next for the share prices of FTSE 100 stocks BP, GlaxoSmithKline and BT?  2021/01/28 07:34:14 The Motley Fool UK
Three FTSE 100 (INDEXFTSE:UKX) titans all report next month. Paul Summers looks at where their share prices have been and where they might go next. The post Where next for the share prices of FTSE 100 stocks BP, GlaxoSmithKline and BT? appeared first on The Motley Fool UK .
   Glaxo kooperiert mit Eli Lilly und Vir bei milden COVID-19-Fällen - Vir-Aktie +59%  2021/01/27 16:20:00 Finanzen CH
Die Pharmaunternehmen untersuchen eine Kombination aus zwei COVID-19-Therapien bei Patienten mit geringem Risiko und leichten bis mittelschweren Symptomen, wie die britische GlaxoSmithKline mitteilte. Im Rahmen der Zusammenarbeit habe
   Glaxo kooperiert mit Eli Lilly und Vir bei milden COVID-19-Fällen - Vir-Aktie +44 Prozent  2021/01/27 15:57:43 Finanzen CH
Die Pharmaunternehmen untersuchen eine Kombination aus zwei COVID-19-Therapien bei Patienten mit geringem Risiko und leichten bis mittelschweren Symptomen, wie die britische GlaxoSmithKline mitteilte. Im Rahmen der Zusammenarbeit habe
   Global Perinatal Infections Market Analysis By Size, Growth Rate, Share, Trends, Key Players, COVID-19 Impact 2020-2027||Arbor Pharmaceuticals, Par Pharmaceutical, Mylan N.V., GlaxoSmithKline Plc., Novartis AG  2020/10/10 15:56:06 OpenPR
“Global Perinatal Infections Market–Industry Trends and Forecast to 2027” New Research Report Added to Databridgemarketresearch.com database. The report width Of pages : 350 Figures: 60 And Tables: 220 in it.The global Perinatal Infections market is highly fragmented and the
   Global Asthma and COPD Smart Inhalers Markets Report 2020 with Profiles of AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Teva Pharma - ResearchAndMarkets.com  2020/10/09 09:39:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Smart Inhalers: Global Markets" report has been added to ResearchAndMarkets.com's offering. The current report offers a comprehensive picture of the smart inhalers market. Smart inhalers prescribed for the treatment of asthma and COPD are included in the scope of the study. The global market's growth is attributed to factors such as the growing prevalence of respiratory diseases, a rise in the world's geriatric population, growing collaboration between pharma and d
   GlaxoSmithKline: An Unusual Defensive Healthcare Play (NYSE:GSK)  2020/10/09 03:26:53 Seeking Alpha
GlaxoSmithKline is in one of its best positions in recent history, with strong financials, a very diversified business and potential for big upside.
   Pazopanib Market To Set Outstanding Growth In Key Regions By 2025 Featuring Renowned Key Players | GlaxoSmithKline, Novartis  2020/10/08 15:20:38 OpenPR
The Pazopanib market 2020 report analyses global acceptance of trends, future growth potential, key drivers, limitations, opportunities, and best practices that are taken place in market. The report also examines growth potential, market sizes and revenue forecasts (2020-2025)across different regions
   Human Rotavirus Vaccine Market Rapidly Growing in Healthcare Sector by 2020-2027 with Prominent Players: Merck & Co.Inc., Bharat Biotech, GlaxoSmithKline plc.  2020/10/08 13:23:04 OpenPR
Rotavirus vaccine is a vaccine used to protect against rotavirus infections, which are the leading cause of severe diarrhea among young children. The vaccines prevent 15–34% of severe diarrhea in the developing world and 37–96% of severe diarrhea in the

 関連キーワード  (医薬品 米国株 グラクソ・スミスクライン GSK )

 twitter  (公式ツイッターやCEOツイッターなど)

GSK動画